Aberrant mRNA splicing generates oncogenic RNA isoforms and contributes to the development and progression of cholangiocarcinoma
- PMID: 30906543
- PMCID: PMC6403481
- DOI: 10.3892/br.2019.1188
Aberrant mRNA splicing generates oncogenic RNA isoforms and contributes to the development and progression of cholangiocarcinoma
Abstract
Cholangiocarcinoma is a lethal biliary cancer, with an unclear molecular pathogenesis. Alternative splicing is a post-transcriptional modification that generates mature mRNAs, which are subsequently translated into proteins. Aberrant alternative splicing has been reported to serve a role in tumor initiation, maintenance and metastasis in several types of human cancer, including cholangiocarcinoma. In this review, the aberrant splicing of genes and the functional contributions of the spliced genes, in the carcinogenesis, progression and aggressiveness of cholangiocarcinoma are summarized. In addition, factors that influence this aberrant splicing that may be relevant as therapeutic targets or prognosis markers for cholangiocarcinoma are discussed.
Keywords: alternative splicing; cholangiocarcinoma; spliced gene.
Figures


Similar articles
-
An aberrantly spliced isoform of anterior gradient-2, AGR2vH promotes migration and invasion of cholangiocarcinoma cell.Biomed Pharmacother. 2018 Nov;107:109-116. doi: 10.1016/j.biopha.2018.07.154. Epub 2018 Aug 4. Biomed Pharmacother. 2018. PMID: 30086457
-
Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.Cancer Treat Res. 2013;158:41-94. doi: 10.1007/978-3-642-31659-3_3. Cancer Treat Res. 2013. PMID: 24222354 Review.
-
Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets.Curr Cancer Drug Targets. 2013 May;13(4):347-61. doi: 10.2174/1568009611313040001. Curr Cancer Drug Targets. 2013. PMID: 23517594 Review.
-
Aberrant posttranscriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression.Adv Cancer Res. 2014;123:67-94. doi: 10.1016/B978-0-12-800092-2.00003-4. Adv Cancer Res. 2014. PMID: 25081526 Review.
-
[Disturbances of alternative splicing in cancer].Postepy Biochem. 2011;57(3):257-65. Postepy Biochem. 2011. PMID: 22235651 Review. Polish.
Cited by
-
Identification of Mutator-Derived Alternative Splicing Signatures of Genomic Instability for Improving the Clinical Outcome of Cholangiocarcinoma.Front Oncol. 2021 May 14;11:666847. doi: 10.3389/fonc.2021.666847. eCollection 2021. Front Oncol. 2021. PMID: 34055632 Free PMC article.
-
Ral GEF with the PH Domain and SH3 Binding Motif 1 Regulated by Splicing Factor Junction Plakoglobin and Pyrimidine Metabolism Are Prognostic in Uterine Carcinosarcoma.Dis Markers. 2021 Oct 28;2021:1484227. doi: 10.1155/2021/1484227. eCollection 2021. Dis Markers. 2021. PMID: 34745385 Free PMC article.
-
Impact of Alternative Splicing Variants on Liver Cancer Biology.Cancers (Basel). 2021 Dec 21;14(1):18. doi: 10.3390/cancers14010018. Cancers (Basel). 2021. PMID: 35008179 Free PMC article. Review.
-
Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma: Current Progress, Mechanisms of Action, and Challenges.Am J Pathol. 2025 Mar;195(3):453-469. doi: 10.1016/j.ajpath.2024.10.021. Epub 2024 Dec 14. Am J Pathol. 2025. PMID: 39675505 Review.
References
-
- Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) Nat Rev Gastroenterol Hepatol 13. 2016:261–280. doi: 10.1038/nrgastro.2016.51. - DOI - PubMed
-
- Thuwajit C, Thuwajit P, Kaewkes S, Sripa B, Uchida K, Miwa M, Wongkham S. Increased cell proliferation of mouse fibroblast NIH-3T3 in vitro induced by excretory/secretory product(s) from Opisthorchis viverrini. Parasitology 129. 2004:455–464. - PubMed
LinkOut - more resources
Full Text Sources